Canaccord Genuity Group Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $60.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective lifted by equities research analysts at Canaccord Genuity Group from $36.00 to $60.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 79.05% from the company’s previous close.

Several other brokerages also recently weighed in on STOK. Chardan Capital reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wolfe Research initiated coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price for the company. Loop Capital set a $35.00 target price on Stoke Therapeutics in a research report on Monday, January 5th. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $33.51 on Friday. The firm’s fifty day simple moving average is $32.61 and its 200-day simple moving average is $30.09. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $40.22.

Insider Activity

In related news, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director directly owned 283,302 shares in the company, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jonathan Allan sold 4,628 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $145,041.52. Following the completion of the transaction, the general counsel directly owned 28,836 shares in the company, valued at $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 69,699 shares of company stock worth $2,526,714 in the last quarter. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $26,000. Harbour Investments Inc. boosted its stake in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after purchasing an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics in the third quarter valued at $41,000. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares in the last quarter.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.